Acceleron Pharma (XLRN) Misses Q4 EPS by 14c, Revenues Beat

Acceleron Pharma (NASDAQ: XLRN) reported Q4 EPS of ($0.44), $0.14 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $39.34 million versus the consensus estimate of $35.89 million.

“2019 was a pivotal year for Acceleron as we achieved the most important milestone to date in our 16-year history-our first U.S. FDA approval,” said Habib Dable, President and Chief Executive Officer of Acceleron. “In November, REBLOZYL® (luspatercept-aamt) became the first and only FDA approved erythroid maturation agent and is now indicated to treat anemia in adults with beta-thalassemia who require regular red blood cell transfusions. The approval of REBLOZYL® marks a huge victory for patients with beta-thalassemia, who-up until now-have been waiting for a better way to treat their anemia. It is also a validation of Acceleron’s scientific platform leveraging our expertise in the TGF-beta superfamily of proteins and our unwavering commitment to develop and commercialize medicines to treat serious and rare diseases.”

Continued Mr. Dable: “While our hematology program remains a top priority, we are equally excited by the progress we are making in pulmonary disease. We recently announced positive topline results from the PULSAR Phase 2 trial of sotatercept for the treatment of PAH. These data introduce the possibility that sotatercept could potentially change the way physicians currently treat patients with PAH. We look forward to presenting the detailed topline results at the American Thoracic Society 2020 International Conference in May and to our upcoming interactions with health authorities as we plan to globally develop and, if approved, commercialize sotatercept in PAH. We also expect to announce topline results from our Phase 2 neuromuscular program in Charcot-Marie-Tooth disease in March.”

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c